Clinical trials: Rivaroxaban
Myeloproliferative Neoplasm
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral anticoagulants (DOACs) may have improved bleeding…
- Trial name
- MPN-DOACs (NCT04192916)
- Testing
- DOACs
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 442 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Healthy Volunteers
A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
Researchers are looking for a better way to treat venous thromboembolic disease, also known as VTE. In people with VTE, blood clots form in the veins of the legs, groin, or arms.
- Trial name
- NCT04727021
- Testing
- 20 mg tablet rivaroxaban, 20 mg rivaroxaban, granules for oral suspension
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy
Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
Prostate cancer ranks second among all malignances in men and has become a significant threat to men's health. Robot-assisted laparoscopic radical prostatectomy (RARP) has become a standard treatment for prostate cancer.
- Conditions
- Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol, Prehabilitation
- Trial name
- NCT05576766
- Testing
- Routine care, ERAS management pathway
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University First Hospital
Anticoagulation With NOAC
Specific PoC Testing of Coagulation in Patients Treated With DOAC 1
The investigators study aims to test the correlation between the Cascade Abrazo point-of-care testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran, edoxaban and rivaroxaban, and to determine…
- Trial name
- SPOCT-DOAC 1 (NCT02825394)
- Testing
- anti-Xa activity point-of-care testing (aXa-POCT), ecarin clotting time point-of-care testing (ECT-POCT)
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- University Hospital Tuebingen
ATRIAL FIBRILLATION
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to standard of care in reducing stroke, transient ischemic attack (TIA) and neurocognitive…
- Trial name
- BRAIN-AF (NCT02387229)
- Testing
- Rivaroxaban, standard of care
- Where
- 41 sites in Canada
- Volunteers
- 1,238 people
- Sponsor
- Montreal Heart Institute
Cerebral Infarction, TIA
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
Anticoagulant treatment for non-valvular atrial fibrillation (AF) associated with cerebral infarction/ TIA is one of the recognized treatment of stroke prevention.
- Trial name
- ERSAF (NCT03749057)
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 400 people
- Sponsor
- General Hospital of Shenyang Military Region
Venous Thromboembolism
Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
The purpose of this study is to compare the efficacy of two prophylactic agent(aspirin 300mg/day and rivaroxaban 10mg/day) for venous thromboembolism after total knee arthroplasty.
- Trial name
- NCT02271399
- Testing
- acetylsalicylic acid, rivaroxaban
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanyang University Seoul Hospital
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Cancer, Stroke
Anticoagulation in Cancer Related Stroke
Purpose: Cancer associated intravascular coagulopathy is the primary mechanism of cancer-related stroke, particularly in those without conventional stroke etiologies.
- Trial name
- OASIS-CANCER (NCT02743052)
- Testing
- Anticoagulation treatment.
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
Venous Thromboembolism
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
The main goal is to provide additional information to the risk-benefit assessment of the drug.
- Trial name
- XAMOS (NCT00831714)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard care treatment for VTE prophylaxis
- Where
- 42 sites in Australia, Austria and 40 more
- Volunteers
- 19,076 people
- Sponsor
- Bayer
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Cerebral Venous Thrombosis
Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis
A total of 72 patients meeting the diagnostic criteria for acute cerebral venous thrombosis were included in this study. A multi-center stratified randomization method was adopted, with the stratification factor being each…
- Trial name
- ABACVT (NCT07352358)
- Testing
- batroxobin, Anticoagulation Agents
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Xuanwu Hospital, Beijing
Rivaroxaban
Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI
The aim of this study is to assess the efficacy and safety of rivaroxaban or aspirin combined with clopidogrel in patients with coronary heart disease and gastrointestinal diseases undergoing PCI.
- Trial name
- NCT04805710
- Testing
- clopidogrel combined with rivaroxaban arm
- Volunteers
- 1,020 people
- Sponsor
- Shenyang Northern Hospital
Superficial Vein Thrombosis
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).
- Trial name
- NCT01499953
- Testing
- Rivaroxaban, Fondaparinux
- Where
- 23 sites in Germany
- Volunteers
- 472 people
- Sponsor
- GWT-TUD GmbH
Atrial Fibrillation
Oral Anticoagulation in Hemodialysis
The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients.
- Trial name
- NCT03799822
- Testing
- Rivaroxaban 10 MG Oral Tablet, MK-7 2000µg thrice weekly, Vitamin K Antagonist - Drug
- Where
- Belgium
- Volunteers
- 132 people
- Sponsor
- Onze Lieve Vrouw Hospital
Kawasaki Disease, Coronary Artery Aneurysm
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed.
- Trial name
- RIVA-KG (NCT05643651)
- Testing
- Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Fudan University
Venous Thrombosis, Neoplasms
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients.
- Conditions
- Venous Thrombosis, Neoplasms, Anticoagulants
- Trial name
- ONCO PE (NCT04724460)
- Testing
- Long DOAC, Short DOAC
- Where
- Japan
- Volunteers
- 179 people
- Sponsor
- Takeshi Morimoto
Venous Thromboembolism
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess different doses of a new drug (BAY 59-7939), taken as a tablet, are safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- ODIXaHIP-OD (NCT00396786)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 62 sites in Austria, Belgium and 11 more
- Volunteers
- 877 people
- Sponsor
- Bayer
Atrial Fibrillation, Coronary Artery Disease
Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
Rationale: Patients with atrial fibrillation who undergo percutaneous coronary intervention for coronary artery disease are treated with antiplatelet therapy on top of a non-vitamin K oral anticoagulant.
- Trial name
- IMPACT AF-PCI (NCT06103266)
- Testing
- Rivaroxaban
- Volunteers
- 50 people
- Sponsor
- J.P.S Henriques
Venous Thromboembolism, Cancer
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH).
- Trial name
- NCT02583191
- Testing
- Rivaroxaban, low-molecular heparine
- Where
- Germany
- Volunteers
- 246 people
- Sponsor
- AIO-Studien-gGmbH